Literature DB >> 33221743

DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer.

Kai Xu1,2, Binshen Chen1,2, Bingkun Li1,2, Chaoming Li1,2, Yiming Zhang1,2, Ning Jiang1,2, Bin Lang3.   

Abstract

The role of DNA methyltransferase 3B (DNMT3B) in tumorigenesis and development has been widely recognized; however, the mechanism underlying its action remains unclear. Considering its function in de novo methylation, we aimed to investigate whether DNMT3B plays its role via microRNA (miR)-34a promoter methylation in bladder cancer. We found that DNMT3B expression was low in 10 bladder cancer tissues and high in 20 bladder cancer tissues. miR-34a expression was higher in bladder cancer tissues with low expression of DNMT3B than that in bladder cancer tissues with high expression of DNMT3B. The level of miR-34a was negatively correlated with the level of DNMT3B. The methylation ratio of the miR-34a promoter was positively correlated with the level of DNMT3B and negatively correlated with the level of miR-34a. DNMT3B knockdown increased the expression of miR-34a and the transcriptional activity of the miR-34a promoter, while decreasing miR-34a promoter methylation. DNMT3B knockdown inhibited migration and invasion, while decreasing the protein levels of hepatocyte nuclear factor 4 gamma and Notch1 which are downstream targets of miR-34a. These inhibitory effects of DNMT3B were mitigated by the miR-34a inhibitor. In conclusion, DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer.

Entities:  

Keywords:  DNA methyltransferase 3B; bladder cancer; metastasis; methylation; miR-34a promotor

Mesh:

Substances:

Year:  2020        PMID: 33221743      PMCID: PMC7762500          DOI: 10.18632/aging.103820

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  32 in total

1.  RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines.

Authors:  A Sowińska; P P Jagodzinski
Journal:  Cancer Lett       Date:  2007-05-29       Impact factor: 8.679

2.  Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.

Authors:  Yuning Xiong; Sean C Dowdy; Ailing Xue; Jiang Shujuan; Norman L Eberhardt; Karl C Podratz; Shi-Wen Jiang
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

3.  Inhibitory effects of microRNA-34a on cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1.

Authors:  Chao Zhang; Zhiyong Yao; Mingyang Zhu; Xin Ma; Taoping Shi; Hongzhao Li; Baojun Wang; Jinzhi Ouyang; Xu Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

4.  DNMT3B polymorphisms and risk of primary lung cancer.

Authors:  Su Jeong Lee; Hyo-Sung Jeon; Jin-Sung Jang; Sun Ha Park; Ga Young Lee; Byung-Heon Lee; Chang Ho Kim; Young Mo Kang; Won Kee Lee; Sin Kam; Rang Woon Park; In-San Kim; Young Lae Cho; Tae Hoon Jung; Jae Yong Park
Journal:  Carcinogenesis       Date:  2004-11-04       Impact factor: 4.944

5.  Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma.

Authors:  Zhisen Shen; Chongchang Zhou; Jinyun Li; Dong Ye; Qun Li; Jian Wang; Xiang Cui; Xiaoying Chen; Tianlian Bao; Shiwei Duan
Journal:  Gene       Date:  2016-07-20       Impact factor: 3.688

6.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G.

Authors:  Huaibin Sun; Jun Tian; Wanhua Xian; Tingting Xie; Xiangdong Yang
Journal:  Dis Markers       Date:  2015-03-23       Impact factor: 3.434

9.  LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.

Authors:  Hong Zhang; Yao-Zhen Pan; May Cheung; Mary Cao; Chao Yu; Ling Chen; Lei Zhan; Zhi-Wei He; Cheng-Yi Sun
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

Review 10.  The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.

Authors:  Cristian Scheau; Ioana Anca Badarau; Raluca Costache; Constantin Caruntu; Gratiela Livia Mihai; Andreea Cristiana Didilescu; Carolina Constantin; Monica Neagu
Journal:  Anal Cell Pathol (Amst)       Date:  2019-11-26       Impact factor: 2.916

View more
  3 in total

Review 1.  Epigenetic modification regulates tumor progression and metastasis through EMT (Review).

Authors:  Tingshan Tan; Pengfei Shi; Muhammad Nadeem Abbas; Yi Wang; Jie Xu; Yu Chen; Hongjuan Cui
Journal:  Int J Oncol       Date:  2022-04-21       Impact factor: 5.884

2.  Understanding of cell death induced by the constituents of Taxus yunnanensis wood.

Authors:  Yukihiro Akao; Riyako Terazawa; Nobuhiko Sugito; Kazuki Heishima; Kohei Morikawa; Yuko Ito; Ryoko Narui; Reo Hamaguchi; Takahiro Nobukawa
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

3.  Promotor Hypomethylation Mediated Upregulation of miR-23b-3p Targets PTEN to Promote Bronchial Epithelial-Mesenchymal Transition in Chronic Asthma.

Authors:  Yimin Guo; Xiaoqing Yuan; Luna Hong; Qiujie Wang; Shanying Liu; Zhaolin Li; Linjie Huang; Shanping Jiang; Jianting Shi
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.